ATR

Aptar Named Among the 100 Best Corporate Citizens for Third Consecutive Year

Retrieved on: 
Wednesday, October 18, 2023
Pharmaceutical, Medical Supplies, Health, Packaging, Chemicals, Plastics, Cosmetics, Manufacturing, Retail, AptarGroup, NYSE, ESG, Human rights, Sustainability reporting, Institutional Shareholder Services, Multimedia, Responsibility, Environment, Climate change, ATR, ISS, Stakeholder

3BL and its partner, Institutional Shareholder Services (ISS) ESG, evaluates the 1,000 largest, publicly traded U.S. companies for this ranking.

Key Points: 
  • 3BL and its partner, Institutional Shareholder Services (ISS) ESG, evaluates the 1,000 largest, publicly traded U.S. companies for this ranking.
  • Aptar is ranked 34 out of the 100 companies evaluated.
  • View the full release here: https://www.businesswire.com/news/home/20231018987837/en/
    Photo: 3BL Media Names Aptar Among 100 Best Corporate Citizens (Graphic: Business Wire)
    “We are pleased to be named in the top 50 of the Best Corporate Citizens by 3BL and to be recognized for the third consecutive year.
  • To view the complete list of 100 Best Corporate Citizens of 2023 and for more information on the methodology used, please visit the 3BL Media website here .

Research Conducted by Florida Cancer Specialists & Research Institute Featured at European Society of Medical Oncology 2023 Congress

Retrieved on: 
Friday, October 20, 2023
Research, Annals of Oncology, ESMO, SERD, Physician, MAPK, Congress, European Society for Medical Oncology, Estate (law), Drug development, B7-H4, Adenoid cystic carcinoma, FIH, Abstract, Oncology, Safety, Cancer, FCS, ATR, Patient, Diagnosis, Conjugation, Pharmaceutical industry, MD

FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain. Five FCS physicians are the first authors and/or co-authors of 12 cancer research studies that will be shared at the global gathering of oncologists, researchers, patient advocates, pharmaceutical representatives and journalists. With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.

Key Points: 
  • FORT MYERS, Fla., Oct. 20, 2023 /PRNewswire/ -- Research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is featured this week among the latest advancements and findings in cancer care at the European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
  • With more than 30,000 members from 168 countries worldwide, ESMO is the leading professional organization for medical oncology.
  • The ESMO Congress 2023 is a global stage for the exchange of potentially practice-changing data and multidisciplinary conversations that will spur transformative therapies against cancer.
  • All of the study abstracts will be published online in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.

Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio

Retrieved on: 
Monday, October 16, 2023
WEE1, Cell cycle, AACR, IND, Therapy, SD, PLK, APRE, PLK1, ATR, Poster, HERG, PLK2, PLK3, Conference, Patient, Toxicity, Pharmaceutical industry

ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors to determine the recommended Phase 2 dose, with a daily dosing administration over a 56-day cycle.

Key Points: 
  • ATRN-119 is in an ongoing Phase 1/2a dose escalation trial in solid tumors to determine the recommended Phase 2 dose, with a daily dosing administration over a 56-day cycle.
  • This preclinical compound exhibits high potency for WEE1 inhibition in vitro and shows low off-target inhibition of the PLK family.
  • The preclinical data findings and sensitivity to our WEE1 asset is guiding our clinical strategy and future patient selection.
  • We look forward to advancing the drug to IND in the fourth quarter of this year.”

Artios to Present Initial Phase 1 Clinical Monotherapy Data for ATR Inhibitor ART0380 in Advanced Solid Tumors at the European Society of Medical Oncology Congress 2023

Retrieved on: 
Thursday, October 5, 2023
Ataxia–telangiectasia, Cancer, University, Pharmacokinetics, Drug development, DNA, Safety, ESMO, ATR, European Society for Medical Oncology, Patient, DDR, Combination therapy, Pharmaceutical industry

CAMBRIDGE, United Kingdom and NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the Company will unveil data from the initial Phase 1 study of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place October 20 to 24, 2023 in Madrid, Spain.

Key Points: 
  • ART0380 is a highly competitive, wholly owned ATR inhibitor with broad clinical application alone or in combination for DDR deficient and high replication stress tumors
    CAMBRIDGE, United Kingdom and NEW YORK, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, announces the Company will unveil data from the initial Phase 1 study of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place October 20 to 24, 2023 in Madrid, Spain.
  • ART0380 is a competitive, oral, highly potent, and selective ATR inhibitor undergoing clinical evaluation as monotherapy in patients with solid tumors as well as in combination with chemotherapies in patients with molecularly selected cancers.
  • Monotherapy data presented will include safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy.
  • First results from the phase I trial of the ATR inhibitor, ART0380, in advanced solid tumors
    Presenter: Kathleen Moore, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, United States of America
    For more information about Artios Pharma Ltd., please contact:
    Media & Investor Relations Contact:

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

Retrieved on: 
Friday, October 13, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, September 5, FRCP, Pharmacokinetics, Doctor of Philosophy, Modularity, Drug, Glomus tumor, MBBS, AACR, Anemia, MD, Traveller Alien Module 1: Aslan, Traveller Alien Module 2: K'kree, Safety, NCT, University, MD Anderson Cancer Center, PPP2R1A, Patient, MRR, RECIST, Therapy, CCNE1, ATR, Trae Waynes, PKMYT1, Genotype, Principal investigator, Neoplasm, Roche, FBXW7, Conference, OR, CBR, Gynecologic cancer disparities in the United States, Pharmaceutical industry, Vaccine, Medical imaging, Dietary supplement, Reparenting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.

Key Points: 
  • Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported positive initial data from Modules 1 and 2 of its ongoing Phase 1 MYTHIC clinical trial evaluating lunresertib alone and in combination with camonsertib, an ATR inhibitor.
  • Lunresertib (RP-6306) is a first-in-class precision oncology small molecule PKMYT1 inhibitor that targets CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors.
  • Lunresertib is being evaluated alone and in combination with camonsertib (RP-3500 / RG6526), a potent and selective oral inhibitor of ATR developed by Repare and now partnered with Roche for development excluding the lunresertib + camonsertib combination.
  • “We saw early efficacy signals across multiple tumor types and in each genotype selected, most notably in gynecological tumors where the lunresertib + camonsertib combination provides a potential new treatment option for these patients.

Aptar Declares Quarterly Dividend

Retrieved on: 
Thursday, October 12, 2023
Pharmaceutical, Medical Supplies, Health, Packaging, Chemicals, Plastics, Cosmetics, Manufacturing, Retail, AptarGroup, Interest, NYSE, Central Time, ATR, Clothing, Cryptocurrency

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.41 per share.

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.41 per share.
  • The payment date is November 16, 2023, to stockholders of record as of October 26, 2023.
  • As previously announced, Aptar will hold a conference call on Thursday, October 26, 2023 at 8:00 a.m. Central Time to discuss the Company’s third quarter results for 2023.
  • Replay of the conference call can also be accessed for a limited time on the Investors page of the website.

General Micro Systems (GMS) X9 Spider Mission Computer Powers Palm-Sized Handheld EW/SIGINT, RF-Enabled Cyber Products from Research Innovations, Inc.

Retrieved on: 
Monday, October 9, 2023
Networks, Other Defense, Hardware, Technology, Defense, Other Manufacturing, Homeland Security, Engineering, Audio, Video, Aerospace, Manufacturing, Public Policy, Government, VPX, M.2, Mitre, NVIDIA, Rain, Acquisition, Vibration, RII, Apple, AI, GMS, Mobile, Aircraft, CONUS, UAS, United States Department of Defense, COTS, Memory, GPGPU, RF, Artificial intelligence, Ministry of Research, Innovation and Science, CUDA, DDR4, EW, SIGINT, MTB, ATR, VME, USB4, War, Xeon W, Hand, Copper, SDR, Noise, Mitre Corporation, Thunderbolt (interface), Video game, Television, Printed circuit board, Tensor, Photon, Spider

RII has ordered the X9 Spider Mission Computer fully equipped with I/O and an NVIDIA® A4500 GPU.

Key Points: 
  • RII has ordered the X9 Spider Mission Computer fully equipped with I/O and an NVIDIA® A4500 GPU.
  • RII’s initial plans for the X9 Spider Mission Computer are for on-the-battlefield mobile, portable and vehicle-mounted use in classified EW / SIGINT applications.
  • The X9 Spider Mission Computer is about 2 x 4.75 x 6 inches, and literally fits in the palm of the hand.
  • X9 Spider Mission Computer now blows open the possibilities for EW / SIGINT RF cyber processing in previously unavailable ways.

Pratt & Whitney Canada Achieves 200th Engine Type Certification - the PW127XT-L Regional Turboprop

Retrieved on: 
Wednesday, October 11, 2023
Aircraft, Certification, NYSE, Engineering, Pratt & Whitney Canada PW100, PT6, Pratt & Whitney Canada, Dornier 328, Trust, Transport Canada, Pratt, Maintenance, ATR, Pratt & Whitney, Aviation, Deutsche Aircraft, Jet fuel, Management, Airline

INNSBRUCK, Austria, Oct. 11, 2023 /PRNewswire/ -- Pratt & Whitney Canada, an RTX (NYSE: RTX) business, announced today that Transport Canada Civil Aviation has type certified the PW127XT-L regional turboprop engine.

Key Points: 
  • INNSBRUCK, Austria, Oct. 11, 2023 /PRNewswire/ -- Pratt & Whitney Canada, an RTX (NYSE: RTX) business, announced today that Transport Canada Civil Aviation has type certified the PW127XT-L regional turboprop engine.
  • This marks another significant milestone for the company as its 200th type certification since the introduction of the original and now ubiquitous PT6 engine in 1963.
  • "Achieving 200 engine type certifications within a 60 year period is truly a singular accomplishment in the world of aviation," said Irene Makris, vice president for customer service at Pratt & Whitney Canada.
  • "This great achievement comes as a reward after many months of hard work and constant collaboration between the ATR and Pratt & Whitney Canada teams."

Global Energy and Chemical Leaders Partner to Develop a Large-Scale, Low-Carbon Ammonia Production Export Project on the Houston Ship Channel

Retrieved on: 
Tuesday, October 3, 2023
Manufacturing, Environmental Issues, Environmental Health, Maritime, Other Energy, Transport, Green Technology, Environment, Energy, Sustainability, Chemicals, Plastics, Workforce, Hydrogen, Steam, Multimedia, ATR, Carbon, LSB, Movement, Liquid nitrogen wash, INPEX, NYSE, Air Liquide, MTPA, VLGC, Ammonia, Water, Natural gas, Engineering, ASU, Houston Ship Channel, Vopak, CO2, TSE, Warehouse, Renewable energy, Industrial gas

The project also has access to utilities and would be near multiple pipelines that could supply raw materials like natural gas and water.

Key Points: 
  • The project also has access to utilities and would be near multiple pipelines that could supply raw materials like natural gas and water.
  • The project partners will bring complementary expertise to the production, operation, storage and export for the advancement of low-carbon ammonia production in the US:
    Air Liquide and INPEX would collaborate on low-carbon hydrogen production.
  • Air Liquide would be responsible for onsite nitrogen and oxygen production, using its proprietary Air Separation Unit (ASU) technology.
  • INPEX, with stakes in both hydrogen and ammonia production, will likely be the largest investor in the overall project across the entire value chain, from production to export.

CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry

Retrieved on: 
Wednesday, September 27, 2023
CABG, Percutaneous coronary intervention, Anticoagulant, International, Bleeding, Intraparenchymal hemorrhage, CET, Boehringer, Dabigatran, STAR, EACTS, Edoxaban, Acute coronary syndrome, International Star Registry, Cytokine adsorbing column, CTD, Research, AstraZeneca, Professional corporation, Eli Lilly, Clopidogrel, DOAC, Boehringer Ingelheim, Incidence, Bayer, Neurosurgery, International Safe Harbor Privacy Principles, Patient, Risk, European Heart Journal, Daiichi Sankyo, Blood, Rivaroxaban, Annual general meeting, Cytosorbents Corporation, United Kingdom, BMS, Cardiology, European Association for Cardio-Thoracic Surgery, Starship Enterprise, Trauma, Ticagrelor, ATR, Pfizer, Birth control, Pharmaceutical industry, Dentistry, Janssen, Aorta, Sanofi

The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.

Key Points: 
  • The International STAR Registry captures high fidelity data on real-world clinical use and associated clinical outcomes using CytoSorb® for antithrombotic drug removal (ATR) in the acute hospital setting.
  • The STAR Registry, not to be confused with the completed U.S. and Canada STAR-T pivotal trial, is enrolling ahead of internal projections with plans for ongoing presentations at large, international conferences.
  • The first registry analysis entitled, “ Insights from the International Safe and Timely Antithrombotic Removal (STAR) Registry ” was presented at the EuroPCR conference in May 2023, the largest interventional cardiology conference in the E.U., attracting 11,500+ participants this year.
  • It also includes, for the first time, data on patients being treated with CytoSorb to reduce seven different antithrombotic medications.